Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab with or without radiotherapy in recurrent or stage IV NSCLC
NCT04513301Phase 2Unknown
- Sponsor
- Fudan University Shanghai Cancer Center
- Start
- Jan 2020
- Primary completion
- Aug 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of sintilimab in non-small cell lung cancer (NSCLC), sponsored by Fudan University Shanghai Cancer Center. Status: unknown.
02
Drugs
sintilimab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04513301.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04513301.